Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin Plus Sorafenib in Advanced HCC
NCT02672488Phase 2Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Dec 2015
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of metformin in hepatocellular carcinoma (HCC) (2 arms), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Overall Survival at 12 months. Status: unknown.
02
Drugs
metformin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02672488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02672488.